SeraCare Introduces New Worldwide HIV Performance Panel

MILFORD, Mass., March 24, 2011 /PRNewswire/ -- SeraCare Life Sciences (Nasdaq: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, announces the launch of its new Worldwide HIV Performance Panel. SeraCare's Performance Panels are unique, value-added products that enable assay developers, regulators and end-users to evaluate and troubleshoot assays using highly characterized, naturally-occurring plasma samples. This new HIV panel presents a group of HIV positive plasma samples with diverse variants of HIV, allowing efficient evaluation of HIV assays against multiple strains of the virus. SeraCare's Worldwide HIV Performance Panel includes 20 members—17 are HIV-1 positive, covering 10 different subtypes, two are HIV-2 positive and one is negative. Plasma was sourced from Africa, Asia, Europe and Central America and includes rare and difficult to source HIV genotypes.

(Logo: http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )

"SeraCare's newest performance panel demonstrates again our commitment to providing critical, hard-to-find materials that can reduce assay development time and speed regulatory approval for our customers," commented Susan Vogt, President and CEO of SeraCare. "Further, the launch of this panel reflects progress in a key strategic initiative at SeraCare. Our industry-leading portfolio of geographically diverse and carefully pedigreed patient samples is a differentiated asset that further solidifies our leadership role in creating specialized panels for diagnostics development."

About SeraCare Life Sciences, Inc.

SeraCare serves the global life sciences industry by providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics. The Company's innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular biomarkers, biobanking and contract research services. SeraCare's quality systems, scientific expertise and state-of-the-art facilities support its customers in meeting the stringent requirements of the highly regulated life sciences industry.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare" or the "Company"). All statements regarding our expected future financial position, results of operations, cash flows, dividends, financing plans, business strategy, budget, projected costs or cost savings, capital expenditures, competitive positions, growth opportunities for existing products or products under development, plans and objectives of management for future operations and markets for stock are forward-looking statements. In addition, forward-looking statements include statements in which we use words such as "expect," "believe," "anticipate," "intend," or similar expressions. Although we believe the expectations reflected in such forward-looking statements are based on reasonable assumptions, we cannot assure you that these expectations will prove to have been correct, and actual results may differ materially from those reflected in the forward-looking statements. Factors that could cause our actual results to differ from the expectations reflected in the forward-looking statements in this press release include, but are not limited to, failure to maintain proper inventory levels, availability of financing, reductions or terminations of government or other contracts, interruption in our supply of products or raw materials, actions of SeraCare's competitors, changes in the regulatory environment, delays in new product introductions, lack of market acceptance of new products, decreased healthcare spending, reduced margins resulting from a shift in revenue towards services, prolonged impairment of sales from changes in our sales organization, absence or loss of acquisition opportunities to higher bidders, potential failure to complete any announced acquisition, and potential failure of any acquisition to produce expected revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.

Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400

Sarah Cavanaugh
MacDougall Biomedical Communications
[email protected]
781-235-3060

SOURCE SeraCare Life Sciences, Inc.